The Evolving Regulatory Landscape for AI-Powered Drug and Diagnostic Development: An Expert Panel

Time: 3:00 pm
day: Day 1 Track B PM


  • What can we expect to change based on this guidance, and what does this mean for pharma clinical development?       
  • What impact should we expect to see in the near-term vs. long-term? What additional evidence needs to be collected to drive that next wave of change?  
  • How can clinical development teams get ahead of these anticipated changes to maximize the impact and benefit to patients and R&D pipeline?